Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 335

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1B
Chunk 335
---
911,631  
     3,366,297 

    Commitments and contingencies (See Note
    11) 
     -   
     -  

    Stockholders’ equity: 

    Preferred stock, no
    shares issued or outstanding at December 31, 2024 and 2023, respectively 
     —  
     — 
  
    Common stock, par value
    $0.007 per share; 100,000,000 shares authorized; 15,576,674 and 9,394,610 shares issued and outstanding as of December 31, 2024 and
    2023, respectively 
     106,593  
     65,762 
  
    Additional paid-in capital 
     56,139,753  
     49,393,972 
  
    Accumulated
    deficit 
     (53,644,310) 
     (44,604,479)
  
    Total
    stockholders’ equity 
     2,602,036  
     4,855,255 

    Total liabilities, and
    stockholders’ equity 
    $6,513,667  
    $8,221,552 

The
accompanying notes are an integral part of these consolidated financial statements.

F-3

bioAffinity
Technologies, Inc.

Consolidated
Statements of Operations

For
the Years Ended December 31, 2024 and 2023

    2024  
    2023 

    Net
    Revenue 
    $9,362,022  
    $2,532,499 

    Operating expenses: 

    Direct costs and expenses 
     5,983,475  
     1,740,884 
  
    Research and development 
     1,461,227  
     1,467,936 
  
    Clinical development 
     321,655  
     256,661 
  
    Selling, general and
    administrative 
     9,943,473  
     6,790,654 
  
    Depreciation
    and amortization 
     605,637  
     249,592 

    Total
    operating expenses 
     18,315,467  
     10,505,727 

    Loss
    from operations 
     (8